Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be ...

Innovative delivery techniques, including high-tech nanoparticles and electroporationdevices, may convey more gene therapies into the clinic.

Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET ...

In today’s fast-paced biotechnology landscape, AMSA Biotech emerges as a trailblazer in the field of regenerative medicine. Driven by a vision of science-led healing and personalized care, the company ...

IntroductionThe global mesenchymal stem cells market is witnessing a significant transformation as advancements in ...